Literature DB >> 11264228

Chronic vascular toxicity of doxorubicin in an organ-cultured artery.

T Murata1, H Yamawaki, M Hori, K Sato, H Ozaki, H Karaki.   

Abstract

1. We investigated the chronic effects of doxorubicin (DXR) on morphological and functional changes in the rabbit mesenteric artery using an organ culture system. 2. In arteries cultured with 0.3 microM DXR for 7 days, the contractions induced by noradrenaline, but not those induced by endothelin-1 or high K(+), were strongly inhibited. This reaction was followed by a decrease in the induction of the alpha(1A)-adrenoceptor without any change in the mRNA level. Inhibition of noradrenaline-induced contractions by DXR was attenuated by superoxide dismutase, and alpha(1A)-adrenoceptor protein expression recovered. 3. In the arteries cultured with 1 microM DXR for 7 days, contractions induced by endothelin-1 or high K(+) and absolute force in the permeabilized muscles were also inhibited. Morphological examinations revealed the existence of concentrated nuclei and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labelling (TUNEL)-positive smooth muscle cells, and internucleosomal DNA fragmentation was also detected, indicating the induction of apoptosis. 4. In the arteries cultured with 10 microM DXR for 7 days, nuclear swelling, karyolysis and random DNA fragmentation indicative of necrosis were observed, and muscle contractility was abolished. 5. These results suggest that 0.3 microM DXR selectively down-regulates the alpha(1A)-adrenoceptor protein expression, resulting in a decrease in the noradrenaline-induced contraction. This down-regulation may be at least partly due to the production of a superoxide radical. DXR also caused a decrease in muscle contractility followed by apoptotic changes at 1 microM and necrotic changes at 10 microM. These changes might be responsible for the disturbance of the circulatory system that is often observed during the course of repetitive chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11264228      PMCID: PMC1572694          DOI: 10.1038/sj.bjp.0703959

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  29 in total

1.  Impairment of EDR by a long-term PDGF treatment in organ-cultured rabbit mesenteric artery.

Authors:  H Yamawaki; K Sato; M Hori; H Ozaki; S Nakamura; H Nakayama; K Doi; H Karaki
Journal:  Am J Physiol       Date:  1999-07

2.  Effect of concentration on the cytotoxic mechanism of doxorubicin--apoptosis and oxidative DNA damage.

Authors:  I Müller; A Jenner; G Bruchelt; D Niethammer; B Halliwell
Journal:  Biochem Biophys Res Commun       Date:  1997-01-13       Impact factor: 3.575

3.  Norepinephrine and GTP-gamma-S increase myofilament Ca2+ sensitivity in alpha-toxin permeabilized arterial smooth muscle.

Authors:  J Nishimura; M Kolber; C van Breemen
Journal:  Biochem Biophys Res Commun       Date:  1988-12-15       Impact factor: 3.575

4.  Therapeutic efficacy and apoptosis and necrosis kinetics of doxorubicin compared with cisplatin, combined with whole-body hyperthermia in a rat mammary adenocarcinoma.

Authors:  N Toyota; F R Strebel; L C Stephens; H Matsuda; T Oshiro; G N Jenkins; J M Bull
Journal:  Int J Cancer       Date:  1998-05-18       Impact factor: 7.396

Review 5.  The anthracycline antineoplastic drugs.

Authors:  R C Young; R F Ozols; C E Myers
Journal:  N Engl J Med       Date:  1981-07-16       Impact factor: 91.245

6.  Effects of doxorubicin and ruthenium red on intracellular Ca2+ stores in skinned rabbit mesenteric smooth-muscle fibres.

Authors:  Y Kanmura; L Raeymaekers; R Casteels
Journal:  Cell Calcium       Date:  1989 Aug-Sep       Impact factor: 6.817

7.  Calyculin A and okadaic acid: inhibitors of protein phosphatase activity.

Authors:  H Ishihara; B L Martin; D L Brautigan; H Karaki; H Ozaki; Y Kato; N Fusetani; S Watabe; K Hashimoto; D Uemura
Journal:  Biochem Biophys Res Commun       Date:  1989-03-31       Impact factor: 3.575

8.  Risk factors for doxorubicin-induced congestive heart failure.

Authors:  D D Von Hoff; M W Layard; P Basa; H L Davis; A L Von Hoff; M Rozencweig; F M Muggia
Journal:  Ann Intern Med       Date:  1979-11       Impact factor: 25.391

9.  Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs.

Authors:  T Noda; T Watanabe; A Kohda; S Hosokawa; T Suzuki
Journal:  Invest New Drugs       Date:  1998       Impact factor: 3.850

10.  Effect of low-dose doxorubicin on calcium content and norepinephrine response in rat aorta.

Authors:  H F Dalske; K Hardy
Journal:  Eur J Cancer Clin Oncol       Date:  1988-06
View more
  13 in total

1.  In vitro and in silico analysis of the vascular effects of asymmetrical N,N-bis(alkanol)amine aryl esters, novel multidrug resistance-reverting agents.

Authors:  F Fusi; M Durante; O Spiga; A Trezza; M Frosini; E Floriddia; E Teodori; S Dei; S Saponara
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-06-28       Impact factor: 3.000

2.  Tissue retention of doxorubicin and its effects on cardiac, smooth, and skeletal muscle function.

Authors:  Reid Hayward; David Hydock; Noah Gibson; Stephanie Greufe; Eric Bredahl; Traci Parry
Journal:  J Physiol Biochem       Date:  2012-08-14       Impact factor: 4.158

Review 3.  From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview.

Authors:  Carlo Gabriele Tocchetti; Christian Cadeddu; Daniela Di Lisi; Saveria Femminò; Rosalinda Madonna; Donato Mele; Ines Monte; Giuseppina Novo; Claudia Penna; Alessia Pepe; Paolo Spallarossa; Gilda Varricchi; Concetta Zito; Pasquale Pagliaro; Giuseppe Mercuro
Journal:  Antioxid Redox Signal       Date:  2017-05-15       Impact factor: 8.401

4.  In vivo bioimaging as a novel strategy to detect doxorubicin-induced damage to gonadal blood vessels.

Authors:  Hadas Bar-Joseph; Irit Ben-Aharon; Moran Tzabari; Galia Tsarfaty; Salomon M Stemmer; Ruth Shalgi
Journal:  PLoS One       Date:  2011-09-09       Impact factor: 3.240

5.  Doxorubicin-induced vascular toxicity--targeting potential pathways may reduce procoagulant activity.

Authors:  Irit Ben Aharon; Hadas Bar Joseph; Moran Tzabari; Boris Shenkman; Nahid Farzam; Mattan Levi; Ruth Shalgi; Salomon M Stemmer; Naphtali Savion
Journal:  PLoS One       Date:  2013-09-20       Impact factor: 3.240

6.  Effects of adriamycin and candesartan on the collagen and elastin of the aorta in rats.

Authors:  Jae-Sun Uhm; Woo-Baek Chung; Jung-Sook Yoon; Yong-Seog Oh; Ho-Joong Youn
Journal:  Clin Hypertens       Date:  2014-09-25

Review 7.  Oxidative Stress and Cellular Response to Doxorubicin: A Common Factor in the Complex Milieu of Anthracycline Cardiotoxicity.

Authors:  Donato Cappetta; Antonella De Angelis; Luigi Sapio; Lucia Prezioso; Michela Illiano; Federico Quaini; Francesco Rossi; Liberato Berrino; Silvio Naviglio; Konrad Urbanek
Journal:  Oxid Med Cell Longev       Date:  2017-10-18       Impact factor: 6.543

Review 8.  Cardiac Nonmyocyte Cell Functions and Crosstalks in Response to Cardiotoxic Drugs.

Authors:  Jessica Gambardella; Bruno Trimarco; Guido Iaccarino; Daniela Sorriento
Journal:  Oxid Med Cell Longev       Date:  2017-10-22       Impact factor: 6.543

Review 9.  Doxorubicin cardiotoxicity and target cells: a broader perspective.

Authors:  Antonella De Angelis; Konrad Urbanek; Donato Cappetta; Elena Piegari; Loreta Pia Ciuffreda; Alessia Rivellino; Rosa Russo; Grazia Esposito; Francesco Rossi; Liberato Berrino
Journal:  Cardiooncology       Date:  2016-03-03

10.  Doxorubicin Induces Inflammatory Modulation and Metabolic Dysregulation in Diabetic Skeletal Muscle.

Authors:  Rashmi Supriya; Bjorn T Tam; Xiao M Pei; Christopher W Lai; Lawrence W Chan; Benjamin Y Yung; Parco M Siu
Journal:  Front Physiol       Date:  2016-07-27       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.